Mitochondrial targeting of alpha-tocopheryl succinate enhances its anti-mesothelioma efficacy

0431276 - BTÚ 2015 RIV GB eng J - Journal Article
Kovářová, Jaromíra - Bajziková, Martina - Vondrusová, Magdaléna - Štursa, Jan - Goodwin, J. - Nguyen, M. - Zobalová, Renata - Pesdar, E.A. - Truksa, Jaroslav - Tomasetti, M. - Dong, L. F. - Neužil, Jiří
Mitochondrial targeting of alpha-tocopheryl succinate enhances its anti-mesothelioma efficacy.
Redox Report. Roč. 19, č. 1 (2014), s. 16-25. ISSN 1351-0002. E-ISSN 1743-2928
R&D Projects: GA ČR(CZ) GAP301/10/1937; GA ČR GAP305/12/1708
Institutional support: RVO:86652036 ; RVO:61388963
Keywords : Vitamin E analogues * Mitochondrial targeting * Reactive oxygen species
Subject RIV: EB - Genetics ; Molecular Biology
Impact factor: 1.522, year: 2014

Malignant mesothelioma (MM) is a fatal neoplastic disease with no therapeutic option. Therefore, the search for novel therapies is of paramount importance. Methods: Since mitochondrial targeting of alpha-tocopheryl succinate (alpha-TOS) by its tagging with triphenylphosphonium enhances its cytotoxic effects to cancer cells, we tested its effect on MM cells and experimental mesotheliomas. Results: Mitochondrially targeted vitamin E succinate (MitoVES) was more efficient in killing MM cells than a-TOS with IC50 lower by up to two orders of magnitude. Mitochondrial association of MitoVES in MM cells was documented using its fluorescently tagged analogue. MitoVES caused apoptosis in MM cells by mitochondrial destabilization, resulting in the loss of mitochondrial membrane potential, generation of reactive oxygen species, and destabilization of respiratory supercomplexes. The role of the mitochondrial complex II in the activity of MitoVES was confirmed by the finding that MM cells with suppressed succinate quinone reductase were resistant to MitoVES. MitoVES suppressed mesothelioma growth in nude mice with high efficacy. Discussion: MitoVES is more efficient in killing MM cells and suppressing experimental mesotheliomas compared with the non-targeted alpha-TOS, giving it a potential clinical benefit.
Permanent Link: http://hdl.handle.net/11104/0235844